Molecular Devices Expands SoftMax® Pro GxP Software Suite with GLP Mode to Help Laboratories Advance Confidently from Discovery Toward Regulated Compliance
PR Newswire
SAN JOSE, Calif., Sept. 17, 2026
New microplate reader software helps laboratories apply appropriate controls as workflows evolve from discovery toward more regulated environments
SAN JOSE, Calif., Sept. 17, 2026 /PRNewswire-PRWeb/ -- Molecular Devices, a Danaher company and a leading provider of high‑performance life science solutions, today introduced SoftMax® Pro 7.6 GLP Mode, the newest addition to the SoftMax Pro 7.6 GxP Software Suite. Designed to support laboratories at different stages of compliance maturity, the new GLP Mode helps teams strengthen data integrity, traceability, and workflow oversight, creating more defendable records, stronger accountability across users, and greater confidence in their data as compliance expectations evolve, without adding unnecessary complexity. The expanded suite helps laboratories apply the right level of control as their work progresses from development and non-clinical research toward more regulated environments.
As biotechnology and pharmaceutical programs advance, laboratories face growing expectations for secure data management, consistent workflow execution, traceable audit trail review, and audit-ready reporting in trusted, controlled software environments. SoftMax Pro 7.6 GLP Mode helps bridge the gap for development-stage laboratories that may not require the extensive infrastructure associated with GMP operations but still need practical governance and oversight tools.
"Customers need compliance solutions that evolve alongside their science, while maintaining consistency across teams, workflows, and operating environments," said Mary Duseau, President of Molecular Devices. "By expanding the SoftMax Pro GxP Software Suite with a purpose-built GLP option, laboratories can take the next practical step toward stronger oversight without adding unnecessary complexity. This connected approach helps teams standardize workflows, strengthen confidence in their data, and accelerate progress from discovery to impact across organizations and geographies."
SoftMax Pro 7.6 GLP Mode adds enhanced user management, electronic signatures, audit-ready reporting, and controls that help standardize data management across teams. As part of the broader SoftMax Pro 7.6 GxP Software Suite, the new mode gives biotechnology, pharmaceutical, contract research, and translational research organizations a practical way to increase oversight of plate reader data and support evolving compliance expectations.
Compatible with the full line of SoftMax Pro SpectraMax® microplate readers, the SoftMax Pro 7.6 GxP Software Suite is now available worldwide. Learn more here.
About Molecular Devices
Molecular Devices, a Danaher Company, is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection, and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California, with offices around the globe. For more information, please visit www.moleculardevices.com.
About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
Media Contact
Amy Smith, Molecular Devices, 1 4083344699, amy.smith@moldev.com
View original content:SOURCE Molecular Devices
